The effect of hemantane on the level of pro-inflammatory cytokines in the nigrocudate complex of the brain of mice with experimental parkinsonism

Abstract

The aim of this work was to study the effect of Hemantane (N-(2-adamantyl)-hexamethyleneimine hydrochloride) on the level of pro-inflammatory cytokines IL-1β, IL-6, interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-α) in the nigrocaudate complex of mice in early and late clinical phases of experimental Parkinsonian syndrome (PS) to elucidate its antiparkinsonian effect.
Material and methods: The early and late clinical phases of PS were created in C57BL / 6J mice by 4 intraperitoneal injections at 2-h intervals of a proneurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), at a dose of 12 mg/kg or 20 mg/kg. Hemantane was injected intraperitoneally at a dose of 20 mg/kg 30 min before each MPTP administration. Concentrations of cytokines in mouse brain structures were measured by enzyme-linked immunosorbent assay (ELISA) using Cloud-Clone Corporation (USA) test systems and an ImmunoChem-2100 (USA) ELISA reader.
Results: Concentrations of IL-1β, IL-6, IFN-γ, and TNF-α in the nigrocaudate complex were increased both in the early and late phases of PS. Prior administration of hemantane reduced the content of IL-1β, IFN-γ, and TNF-α in the nigrocaudate complex at the early phase and the content of only one of the 4 studied cytokines (IL-6) at the late phase of PS. It was assumed that the antiparkinsonian effect of hemantane at the early clinical stage of MPTP-induced PS involves a decrease in proinflammatory cytokines in the nigrostriatal system, which prevents the impairment of the viability of dopaminergic neurons.